BACK

Reported Italy pause of a batch of the Oxford AstraZeneca vaccine as a precaution after two deaths in Sicily

Update

It has been reported that Italy has paused vaccination with the Oxford-AstraZeneca COVID-19 vaccine as a precaution following the deaths of two men in Sicily.

This article was published on
March 11, 2021

This explainer is more than 90 days old. Some of the information might be out of date or no longer relevant. Browse our homepage for up to date content or request information about a specific topic from our team of scientists.

Publication

What our experts say

Context and background

Resources

Media briefing

Media Release

Expert Comments: 

Prof Stephen Evans

There are a number of countries that have paused the use of the AZ vaccine, in some countries related to a particular batch.  Genuine problems with a batch are very rare and almost always relate to contamination by bacteria or physical (e.g. glass) particles detected by the manufacturer.  Pausing the use in this case is not evidence-based and as the European Medicines Agency states in the headline to its comment “COVID-19 Vaccine AstraZeneca: PRAC preliminary view suggests no specific issue with batch used in Austria” and it is the batch that has also been paused in Italy.

It is not known whether there are non-scientific reasons for the actions taken by some EU countries.

Prof Anthony Harnden

Vaccine safety is critically important.  Our UK regulator, the MHRA, review all reports of adverse events for both vaccines as they are reported.  There have been more than 11 million doses of the Oxford-AZ vaccine administered in the UK and no excess reports of deaths or blood clots amongst those receiving the vaccine, compared with the expected rate in the population.  The public should have confidence that both vaccines used in the UK vaccination programme are safe and highly effective at preventing severe disease, including blood clots and deaths caused by Covid.

Q&A

No items found.